Shinya Kai

Dr. Shinya Kai


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YKYoshihide Kuribayashi
Yoshihide Kuribayashi
SMShigekiyo Matsumoto
Shigekiyo Matsumoto
YOYoshifumi Ohchi
Yoshifumi Ohchi
SKShinya Kai
Shinya Kai
YOYoshimasa Oyama
Yoshimasa Oyama
CSChihiro Shingu
Chihiro Shingu
Objectives: Oxidative stress after cardiac surgery may disrupt the blood–brain barrier and contribute to postoperative delirium (POD). Although associations between oxidative stress and POD are recognized, whether vitamin C (VC) can prevent POD remains poorly understood. This study aimed to explore the association of VC administration with POD after cardiac surgery. Methods: Eighty-four patients undergoing elective cardiac surgery at our hospital were enrolled. The non-VC group (NVC, n = 40) consisted of patients treated between October 2021 and March 2022, while the VC group (n = 44) included those treated between April and September 2022 who received 2 g intravenous VC at intensive care unit (ICU) admission. The primary outcome was POD incidence. Electron spin resonance (ESR) measured AFR/DMSO, which reflected VC before induction, after CPB withdrawal, at ICU admission, and on postoperative day 1. Results: Baseline characteristics, comorbidities, and intraoperative factors were similar between groups. Postoperative organ dysfunction and inflammation were also comparable, although lactate levels were 40% higher in the VC group. POD incidence was significantly lower with VC (35.0% vs. 11.4%, p < 0.01). Logistic regression analysis confirmed that VC reduced POD risk (adjusted odds ratio 0.22, 95% CI 0.07–0.69, p < 0.01). ESR showed that postoperative AFR/DMSO levels dropped sharply but normalized by day 1 in VC-treated patients. Conclusions: This study suggests that 2 g of VC administered at ICU admission may reduce POD incidence. In the future, these findings require confirmation in randomized trials.